Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 8/20 | 0.69 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.60 |
| ▸ | ADRB3 known ✓ | P13945 | 8/20 | 0.57 |
| ▸ | ADRB1 known ✓ | P08588 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28435051 | 1.00 | ADRB2 (0.69) | ADRB2KDM4EGAASMN1; SMN2TDP1 | |
| Hydrochloric Acid SCHEMBL28435050 | 1.00 | ADRB2 (0.69) | ADRB2KDM4EGAASMN1; SMN2TDP1 | |
| Hydrochloric Acid SCHEMBL28662709 | 1.00 | ADRB2 (0.69) | ADRB2KDM4EGAASMN1; SMN2TDP1 | |
| SCHEMBL16596122 | 0.98 | ADRB2 (0.71) | ADRB2KDM4EGAASMN1; SMN2TDP1 | |
| SCHEMBL7118929 | 0.98 | ADRB2 (0.71) | ADRB2KDM4EGAASMN1; SMN2TDP1 | |
| SCHEMBL28582068 | 0.98 | ADRB2 (0.71) | ADRB2KDM4EGAASMN1; SMN2TDP1 | |
| SCHEMBL10720145 | 0.87 | ADRB2 (0.77) | ADRB2KDM4EGAASMN1; SMN2TDP1 | |
| SCHEMBL4467889 | 0.84 | ADRB2 (0.73) | ADRB2KDM4EGAASMN1; SMN2TDP1 | |
| SCHEMBL4467885 | 0.84 | ADRB2 (0.73) | ADRB2KDM4EGAASMN1; SMN2TDP1 | |
| SCHEMBL9543386 | 0.84 | ADRB2 (0.73) | ADRB2KDM4EGAASMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051295-A1 | PROCESS FOR THE PREPARATION OF MIRABEGRON FREE FROM GENOTOXIC IMPURITIES | ZYDUS LIFESCIENCES LIMITED (IN) | 2025-02-13 | — | — | US | claimed |
| WO-2015155664-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF 2-(2-AMINOTHIAZOL-4-YL)-N-[4-(2-[[(2R)-2-HYDROXY-2- PHENYLETHYL]AMINO]-ETHYL)PHENYL]ACETAMIDE | SUVEN LIFE SCIENCES LIMITED (IN) | 2015-10-15 | — | — | WO | claimed |
| WO-2014132270-A2 | PROCESS FOR THE PREPARATION OF 2-(2-AMINOTHIAZOL-4-YL)-N-[4-(2-{[(2R)-2-HYDROXY-2-PHENYL ETHYL]AMINO}ETHYL)PHENYL]ACETAMIDE MONOHYDROCHLORIDE, ITS INTERMEDIATES AND POLYMORPH THEREOF | MSN LABORATORIES LIMITED (IN) | 2014-09-04 | — | — | WO | claimed |
| US-20250051295-A1 | PROCESS FOR THE PREPARATION OF MIRABEGRON FREE FROM GENOTOXIC IMPURITIES | ZYDUS LIFESCIENCES LIMITED (IN) | 2025-02-13 | — | — | US | disclosed |
| CN-113816864-A | Preparation method of (R) -2-hydroxy-N- [2- (4-aminophenyl) ethyl ] -2-phenylethylamine | 南京正大天晴制药有限公司 | 2021-12-21 | — | — | CN | disclosed |
| CN-113773274-A | Recrystallization method of mirabegron alpha crystal form raw material | 石药集团中奇制药技术（石家庄）有限公司 | 2021-12-10 | — | — | CN | disclosed |
| US-9815771-B2 | Method for the synthesis of mirabegron and its derivatives | INTERQUIM, S.A. (ES) | 2017-11-14 | — | — | US | disclosed |
| US-20170291882-A1 | Solid Forms of Mirabegron | APOTEX INC. (CA) | 2017-10-12 | — | — | US | disclosed |
| WO-2016049749-A1 | SOLID FORMS OF MIRABEGRON | APOTEX INC. (CA) | 2016-04-07 | — | — | WO | disclosed |
| WO-2015155664-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF 2-(2-AMINOTHIAZOL-4-YL)-N-[4-(2-[[(2R)-2-HYDROXY-2- PHENYLETHYL]AMINO]-ETHYL)PHENYL]ACETAMIDE | SUVEN LIFE SCIENCES LIMITED (IN) | 2015-10-15 | — | — | WO | disclosed |
| WO-2015044965-A1 | A PROCESS FOR PREPARATION OF MIRABEGRON AND ALPHA CRYSTALLINE FORM THEREOF | MEGAFINE PHARMA (P) LTD. (IN) | 2015-04-02 | — | — | WO | disclosed |
| US-7750029-B2 | administering (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide; treating urogenital disorders | ASTELLAS PHARMA INC. (JP) | 2010-07-06 | — | — | US | disclosed |
| US-20090093529-A1 | REMEDY FOR OVERACTIVE BLADDER COMPRISING ACETIC ACID ANILIDE DERIVATIVE AS THE ACTIVE INGREDIENT | ASTELLAS PHARMA INC. | 2009-04-09 | — | — | US | disclosed |
| US-20080214633-A1 | Alpha-form or beta-form crystal of acetanilide derivative | ASTELLAS PHARMA INC. | 2008-09-04 | — | — | US | disclosed |
| EP-1932838-A2 | Beta-form crystal of acetanilide derivative | Astellas Pharma Inc. (JP) | 2008-06-18 | — | — | EP | disclosed |
| US-7342117-B2 | (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]-acetanilide; free base forms; stability; moisture resistance | ASTELLAS PHARMA INC. (JP) | 2008-03-11 | — | — | US | disclosed |
| US-20060115540-A1 | administering (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide; treating urogenital disorders | ASTELLAS PHARMA INC. (JP) | 2006-06-01 | — | — | US | disclosed |
| EP-1559427-A1 | REMEDY FOR OVERACTIVE BLADDER COMPRISING ACETIC ACID ANILIDE DERIVATIVE AS THE ACTIVE INGREDIENT | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2005-08-03 | — | — | EP | disclosed |
| US-20050004190-A1 | Alpha-form or beta-form crystal of acetanilide derivative | ASTELLAS PHARMA INC. (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-1440969-A1 | ALPHA-FORM OR BETA-FORM CRYSTAL OF ACETANILIDE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004190-A1 | Alpha-form or beta-form crystal of acetanilide derivative | IAPP, AMY1A, AMY2A | ADRB2 329/4885GAA 160/4885ADRB3 635/4885 |
| US-20090093529-A1 | REMEDY FOR OVERACTIVE BLADDER COMPRISING ACETIC ACID ANILIDE DERIVATIVE AS THE ACTIVE INGREDIENT | MYLK, ALKBH2, MYH2 | ADRB2 165/4885GAA 2959/4885ADRB3 600/4885 |
| US-20170291882-A1 | Solid Forms of Mirabegron | APOB, APOL1, GPR119 | ADRB2 18/4885GAA 1073/4885ADRB3 11/4885 |
| US-20250051295-A1 | PROCESS FOR THE PREPARATION OF MIRABEGRON FREE FROM GENOTOXIC IMPURITIES | UGT1A6, UGT1A1, UGT1A3 | ADRB2 30/4885GAA 918/4885ADRB3 4/4885 |
| US-20060115540-A1 | administering (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide; treating urogenital disorders | MYLK, RYR2, UTS2R | ADRB2 37/4885GAA 3954/4885ADRB3 214/4885 |
| US-20080214633-A1 | Alpha-form or beta-form crystal of acetanilide derivative | IAPP, AMY1A, AMY2A | ADRB2 351/4885GAA 155/4885ADRB3 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.